|
Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer Clinical research trials and Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer. Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer  Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
For Condition: Adenocarcinoma,Stomach Neoplasms
Status: Recruiting
Sponsor(s): OSI Pharmaceuticals ,
Synopsis: Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Documented locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - No prior chemotherapy for locally advanced or metastatic disease - Adequate baseline bone marrow, hepatic and renal function - Age >= 18 years - At least one target lesion Exclusion Criteria: - Active or uncontrolled infections or other serious illnesses or other medical conditions (eg, hepatitis, HIV, chronic alcohol abuse) - Symptomatic brain metastases which are not stable
Total Enrollment: 43
Location and Contact Information:
Cookridge Hospital *Recruiting*
Leeds, , LS16 6BB
United Kingdom
Recruiting OSIP Information (800) 572-1932
University of Utah, Huntsman Cancer Institute *Not yet recruiting*
Salt Lake City, Utah, 84112
United States
Not yet recruiting OSIP Information 800-572-1932
Christie Hospital NHS Trust *Recruiting*
Manchester, , M20 4BX
United Kingdom
Recruiting OSIP Information (800) 572-1932
New Cross Hospital *Recruiting*
Wolverhampton, , WV10 0QP
United Kingdom
Recruiting OSIP Information (800) 572-1932
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting OSIP Information 800-572-1932
Churchill Hospital *Recruiting*
Headington, Oxford, OX3 7LJ
United Kingdom
Recruiting OSIP Information (800) 572-1932
University of Pennsylvania Cancer Center *Not yet recruiting*
Philadelphia, Pennsylvania, 19104
United States
Not yet recruiting OSIP Information 800-572-1932
Dept Internal Medicine Gastrointestinal Oncology Unit *Not yet recruiting*
B-3000 Leuven, ,
Belgium
Not yet recruiting OSIP Information (800) 572-1932
Belfast City Hospital *Not yet recruiting*
Belfast, , BT9 7AB
United Kingdom
Not yet recruiting OSIP Information (800) 572-1932
University of Glasgow *Recruiting*
Glasgow, , G11 6NT
United Kingdom
Recruiting OSIP Information (800) 572-1932
Bristol Haematology & Oncology Centre *Recruiting*
Bristol, Avon, BS2 8ED
United Kingdom
Recruiting OSIP Information (800) 572-1932
Additional Information:
Study ID Numbers: OSI-904-201;
Study Start Date: October 2003
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073502
Other Stomach Neoplasms Studies:
1. Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
2. Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
3. Phase II Study of MDX-010 in Stage IV Breast Cancer
4. Tezacitabine with or without 5-Fluorouracil (5-FU) for advanced esophageal cancer or gastric cancer
Related Studies:
Other Stomach Neoplasms Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Phase II Study of Single Agent OSI-7904L in patients with Gastric or Gastroesophageal (GEJ) Cancer
|
|
|
|
|
|
|
|
